Search - tctmd.com

Displaying 141 - 160 of 230

Sort: Relevancy | Date

News Daily News

双倍剂量的氯吡格雷可以解决“吸烟者悖论”：GRAVITAS 分析

Michael O'Riordan

February 28, 2016

News Daily News

Análisis del Ensayo GRAVITAS: La ‘Paradoja del Fumador’ Desaparece con Dosis Dobles de Clopidogrel

Michael O'Riordan

February 28, 2016

News Industry News

Meta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference

February 22, 2016

News Daily News

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

December 23, 2015

News Daily News

Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI

Yael L. Maxwell

December 22, 2015

News Daily News

Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines

Yael L. Maxwell

December 14, 2015

News Conference News AHA 2015

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Yael L. Maxwell

November 10, 2015

News Industry News

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

October 15, 2015

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

News Daily News

在已有侵入性策略安排的NSTE-ACS患者中，上游比伐卢定的效果最好

L.A. McKeown

September 21, 2015

News Daily News

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

L.A. McKeown

September 21, 2015

News Daily News

Bivalirudina Upstream en Pacientes SCASEST resulta Óptima Con Estrategia Invasiva Programada

L.A. McKeown

September 21, 2015

Presentation

Impact of Anticoagulation Regimen Prior toRevascularization in Patients With NSTE-ACS

Presenter: Tobias Geisler

September 18, 2015

News Conference News ESC 2015

Meta-analysis: Long-Term DAPT Beneficial for Patients With History of MI

Yael L. Maxwell

August 31, 2015

News Daily News

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

August 04, 2015

News Industry News

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

July 29, 2015

News Daily News

肺栓塞发作后，二级抗凝效果未持续

L.A. McKeown

July 13, 2015

News Daily News

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

L.A. McKeown

July 13, 2015

News Daily News

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

L.A. McKeown

July 13, 2015

Presentation

6 Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism

Presenter: Francis Couturaud

July 10, 2015

Advertisement

双倍剂量的氯吡格雷可以解决“吸烟者悖论”：GRAVITAS 分析

Análisis del Ensayo GRAVITAS: La ‘Paradoja del Fumador’ Desaparece con Dosis Dobles de Clopidogrel

Meta-Analysis of AGGRASTAT® (Tirofiban HCl) Presented at CRT 2016 Conference

Year in Review: Physicians Select the Most Important News of 2015, in Interventional Cardiology and Beyond

Triple Therapy, Especially With Prasugrel, Increases Bleeding Risk in Acute MI

Case Study Highlights Risks for A-fib Patients Undergoing PCI in Absence of Evidence-Based Guidelines

Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

在已有侵入性策略安排的NSTE-ACS患者中，上游比伐卢定的效果最好

Upstream Bivalirudin Best in NSTE-ACS Patients With Planned Invasive Strategy

Bivalirudina Upstream en Pacientes SCASEST resulta Óptima Con Estrategia Invasiva Programada

Impact of Anticoagulation Regimen Prior toRevascularization in Patients With NSTE-ACS

Meta-analysis: Long-Term DAPT Beneficial for Patients With History of MI

Triple Therapy Yields No Thrombotic Benefit, More Bleeding in Older PCI Patients With A-fib

First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate)

肺栓塞发作后，二级抗凝效果未持续

Después de Sufrir un Embolismo Pulmonar el Beneficio de la Anticoagulación Secundaria No se Mantiene

After Pulmonary Embolism, Benefit of Secondary Anticoagulation Does Not Persist

6 Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content